Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516756-18-00

Acronym

116130

Enrollment

Registered

2025-06-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Brief summary

The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic OFF-state.

Detailed description

The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic ON-state., The effect of atomoxetine vs placebo on brain network topology, as calculated by the average integration/segregation coefficient.

Interventions

DRUGAtomoxetine Aurobindo 40 mg hard capsules

DRUGMicrocrystalline cellulose gelatin capsule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic OFF-state.	—

Secondary

Measure	Time frame
The effect of atomoxetine vs. placebo on the percentage of time frozen during FOG-provoking gait tasks in the dopaminergic ON-state., The effect of atomoxetine vs placebo on brain network topology, as calculated by the average integration/segregation coefficient.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026